202 related articles for article (PubMed ID: 37013719)
1. An evaluation of setmelanotide injection for chronic weight management in adult and pediatric patients with obesity due to Bardet-Biedl syndrome.
Lazareva J; Brady SM; Yanovski JA
Expert Opin Pharmacother; 2023 Apr; 24(6):667-674. PubMed ID: 37013719
[TBL] [Abstract][Full Text] [Related]
2. Interview-Based Patient- and Caregiver-Reported Experiences of Hunger and Improved Quality of Life with Setmelanotide Treatment in Bardet-Biedl Syndrome.
Ervin C; Norcross L; Mallya UG; Fehnel S; Mittleman RS; Webster M; Haqq AM; Haws RM
Adv Ther; 2023 May; 40(5):2394-2411. PubMed ID: 36961653
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period.
Haqq AM; Chung WK; Dollfus H; Haws RM; Martos-Moreno GÁ; Poitou C; Yanovski JA; Mittleman RS; Yuan G; Forsythe E; Clément K; Argente J
Lancet Diabetes Endocrinol; 2022 Dec; 10(12):859-868. PubMed ID: 36356613
[TBL] [Abstract][Full Text] [Related]
4. Effect of setmelanotide, a melanocortin-4 receptor agonist, on obesity in Bardet-Biedl syndrome.
Haws R; Brady S; Davis E; Fletty K; Yuan G; Gordon G; Stewart M; Yanovski J
Diabetes Obes Metab; 2020 Nov; 22(11):2133-2140. PubMed ID: 32627316
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials.
Clément K; van den Akker E; Argente J; Bahm A; Chung WK; Connors H; De Waele K; Farooqi IS; Gonneau-Lejeune J; Gordon G; Kohlsdorf K; Poitou C; Puder L; Swain J; Stewart M; Yuan G; Wabitsch M; Kühnen P;
Lancet Diabetes Endocrinol; 2020 Dec; 8(12):960-970. PubMed ID: 33137293
[TBL] [Abstract][Full Text] [Related]
6. Setmelanotide: a promising advancement for pediatric patients with rare forms of genetic obesity.
Trapp CM; Censani M
Curr Opin Endocrinol Diabetes Obes; 2023 Apr; 30(2):136-140. PubMed ID: 36722447
[TBL] [Abstract][Full Text] [Related]
7. Quality of life improvements following one year of setmelanotide in children and adult patients with Bardet-Biedl syndrome: phase 3 trial results.
Forsythe E; Haws RM; Argente J; Beales P; Martos-Moreno GÁ; Dollfus H; Chirila C; Gnanasakthy A; Buckley BC; Mallya UG; Clément K; Haqq AM
Orphanet J Rare Dis; 2023 Jan; 18(1):12. PubMed ID: 36647077
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency.
Collet TH; Dubern B; Mokrosinski J; Connors H; Keogh JM; Mendes de Oliveira E; Henning E; Poitou-Bernert C; Oppert JM; Tounian P; Marchelli F; Alili R; Le Beyec J; Pépin D; Lacorte JM; Gottesdiener A; Bounds R; Sharma S; Folster C; Henderson B; O'Rahilly S; Stoner E; Gottesdiener K; Panaro BL; Cone RD; Clément K; Farooqi IS; Van der Ploeg LHT
Mol Metab; 2017 Oct; 6(10):1321-1329. PubMed ID: 29031731
[TBL] [Abstract][Full Text] [Related]
9. Setmelanotide: First Approval.
Markham A
Drugs; 2021 Feb; 81(3):397-403. PubMed ID: 33638809
[TBL] [Abstract][Full Text] [Related]
10. The efficacy and safety of setmelanotide in individuals with Bardet-Biedl syndrome or Alström syndrome: Phase 3 trial design.
Haws RM; Gordon G; Han JC; Yanovski JA; Yuan G; Stewart MW
Contemp Clin Trials Commun; 2021 Jun; 22():100780. PubMed ID: 34013094
[TBL] [Abstract][Full Text] [Related]
11. Bardet-Biedl syndrome: A clinical overview focusing on diagnosis, outcomes and best-practice management.
Shoemaker A
Diabetes Obes Metab; 2024 Apr; 26 Suppl 2():25-33. PubMed ID: 38383825
[TBL] [Abstract][Full Text] [Related]
12. Understanding the Patient Experience of Hunger and Improved Quality of Life with Setmelanotide Treatment in POMC and LEPR Deficiencies.
Wabitsch M; Fehnel S; Mallya UG; Sluga-O'Callaghan M; Richardson D; Price M; Kühnen P
Adv Ther; 2022 Apr; 39(4):1772-1783. PubMed ID: 35192151
[TBL] [Abstract][Full Text] [Related]
13. [Improved Care and Treatment Options for Patients with Hyperphagia-Associated Obesity in Bardet-Biedl Syndrome].
Cetiner M; Bergmann C; Bettendorf M; Faust J; Gäckler A; Gillissen B; Hansen M; Kerber M; Klaus G; König J; Kühlewein L; Oh J; Richter-Unruh A; von Schnurbein J; Wabitsch M; Weihrauch-Blüher S; Pape L
Klin Padiatr; 2024 Mar; ():. PubMed ID: 38458231
[TBL] [Abstract][Full Text] [Related]
14. Quality of life outcomes in two phase 3 trials of setmelanotide in patients with obesity due to LEPR or POMC deficiency.
Kühnen P; Wabitsch M; von Schnurbein J; Chirila C; Mallya UG; Callahan P; Gnanasakthy A; Poitou C; Krabusch PM; Stewart M; Clément K
Orphanet J Rare Dis; 2022 Feb; 17(1):38. PubMed ID: 35123544
[TBL] [Abstract][Full Text] [Related]
15. Structural analysis of setmelanotide binding to MC4R variants in comparison to wild-type receptor.
Hammad MM; Mohammad A; Alam-Eldin N; Madhu D; Al-Mulla F; Abu-Farha M; Abubaker J
Life Sci; 2022 Oct; 307():120857. PubMed ID: 35931197
[TBL] [Abstract][Full Text] [Related]
16. Melanocortin 4 Receptor Pathway Dysfunction in Obesity: Patient Stratification Aimed at MC4R Agonist Treatment.
Ayers KL; Glicksberg BS; Garfield AS; Longerich S; White JA; Yang P; Du L; Chittenden TW; Gulcher JR; Roy S; Fiedorek F; Gottesdiener K; Cohen S; North KE; Schadt EE; Li SD; Chen R; Van der Ploeg LHT
J Clin Endocrinol Metab; 2018 Jul; 103(7):2601-2612. PubMed ID: 29726959
[TBL] [Abstract][Full Text] [Related]
17. Could setmelanotide be the game-changer for acquired hypothalamic obesity?
van Santen HM; Denzer C; Müller HL
Front Endocrinol (Lausanne); 2023; 14():1307889. PubMed ID: 38239988
[TBL] [Abstract][Full Text] [Related]
18. Requirement of Bardet-Biedl syndrome proteins for leptin receptor signaling.
Seo S; Guo DF; Bugge K; Morgan DA; Rahmouni K; Sheffield VC
Hum Mol Genet; 2009 Apr; 18(7):1323-31. PubMed ID: 19150989
[TBL] [Abstract][Full Text] [Related]
19. Bardet-Biedl syndrome: Weight patterns and genetics in a rare obesity syndrome.
Pomeroy J; Krentz AD; Richardson JG; Berg RL; VanWormer JJ; Haws RM
Pediatr Obes; 2021 Feb; 16(2):e12703. PubMed ID: 32700463
[TBL] [Abstract][Full Text] [Related]
20. Diabetes mellitus in Bardet Biedl syndrome.
Pomeroy J; Offenwanger KM; Timmler T
Curr Opin Endocrinol Diabetes Obes; 2023 Feb; 30(1):27-31. PubMed ID: 36476576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
